We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

64 hedge funds and large institutions have $268M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

20% more capital invested

Capital invested by funds: $222M → $268M (+$45.5M)

5% more funds holding

Funds holding: 6164 (+3)

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

Holders
64
Holders Change
+3
Holders Change %
+4.92%
% of All Funds
1.6%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
11
Increased
16
Reduced
22
Closed
8
Calls
$1.35M
Puts
Net Calls
+$1.35M
Net Calls Change
+$381K
Name Holding Trade Value Shares
Change
Change in
Stake
GPP
1
Great Point Partners
Connecticut
$33.3M +$2.17M +230,575 +8%
BBA
2
Baker Bros. Advisors
New York
$27.4M
RCM
3
RA Capital Management
Massachusetts
$20.2M
DA
4
DSC Advisors
Illinois
$17.3M -$1.01M -107,377 -6%
Franklin Resources
5
Franklin Resources
California
$17.1M
MMH
6
Menora Mivtachim Holdings
Israel
$15M
PA
7
Perceptive Advisors
New York
$14.7M -$473K -50,290 -4%
DM
8
Deerfield Management
New York
$13.7M -$698K -74,214 -6%
TCM
9
Tekla Capital Management
Massachusetts
$10.3M -$336K -35,667 -4%
VC
10
Vivo Capital
California
$9.49M
DCM
11
Driehaus Capital Management
Illinois
$8.86M +$79.7K +8,475 +1%
O
12
OppenheimerFunds
New York
$7.81M +$6.62M +703,658 New
Axa
13
Axa
France
$7.69M
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$7.26M +$35K +3,716 +0.6%
SAM
15
Senzar Asset Management
New York
$6.12M +$260K +27,600 +5%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$5.78M -$37.5K -3,988 -0.8%
BFA
17
BlackRock Fund Advisors
California
$5.68M +$942K +100,072 +24%
OM
18
Opaleye Management
Massachusetts
$5.5M -$1.27M -135,000 -21%
FHAM
19
Folger Hill Asset Management
New York
$4.32M -$1.16M -123,409 -24%
GTC
20
Ghost Tree Capital
New York
$4.05M +$1.95M +207,038 +131%
SFM
21
Sphera Funds Management
Israel
$3.8M
Millennium Management
22
Millennium Management
New York
$3.1M +$1.92M +204,054 +271%
DCM
23
DAFNA Capital Management
California
$2.98M -$94.1K -10,000 -4%
Baillie Gifford & Co
24
Baillie Gifford & Co
United Kingdom
$2.44M
IBT
25
International Biotechnology Trust
United Kingdom
$2.2M +$1.86M +197,838 New

FOMX Hedge Fund Activity: Q4 2016 in Review

64 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2016, worth a combined $268M — up 20% from $222M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FOMX positions and 8 closed out — a net gain of 3 holders — while 16 added to existing stakes and 22 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $6.62M. The largest seller was Barclays, cutting an estimated $2.46M.

  • 64 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2016, up from 61 in Q3 2016.
  • Funds reported $268M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2016, up 20% quarter-over-quarter.
  • 11 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2016 and 8 closed out, a net change of +3 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2016 was OppenheimerFunds, an estimated $6.62M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2016 was Barclays, an estimated $2.46M sold.

Based on aggregated 13F filings for Q4 2016.